The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Dyskinesia, Drug-Induced

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dyskinesia, Drug-Induced


Psychiatry related information on Dyskinesia, Drug-Induced


High impact information on Dyskinesia, Drug-Induced


Chemical compound and disease context of Dyskinesia, Drug-Induced


Biological context of Dyskinesia, Drug-Induced

  • Analysis of covariance (ANCOVA), controlling for age at first antipsychotic treatment, revealed a significant effect of 5-HT2C genotype on orofacial dyskinesia (OFD) scores (F=3.47, df 2, P=.03) [18].
  • We investigated the role of oxidative stress in the pathophysiology of haloperidol (HP)-induced orofacial dyskinesia and evaluated the beneficial effect of Withania somnifera (Ws) root extract in the amelioration of HP-induced vacuous chewing movements (VCMs) and tongue protrusions in the rat model for TD [19].

Anatomical context of Dyskinesia, Drug-Induced


Gene context of Dyskinesia, Drug-Induced

  • Among patients withdrawn from neuroleptics, those with an oral dyskinesia had significantly lower peak GH concentration 2.46 +/- 0.93 ng/ml) after apomorphine compared with those without (14.85 +/- 3.83 ng/ml) (P less than 0.05) [24].
  • Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy [24].
  • Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia [25].
  • OBJECTIVE: The objective of the present study was to elucidate the role of N-methyl-D-aspartate (NMDA) receptor involvement in neuroleptic-induced orofacial dyskinesia in rats [26].
  • The present results suggest that NK3 receptor-active peptides might be symptom inducers in oral dyskinesia [27].

Analytical, diagnostic and therapeutic context of Dyskinesia, Drug-Induced


  1. Pharmacological options for the management of dyskinesias. Shale, H., Tanner, C. Drugs (1996) [Pubmed]
  2. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. van Kampen, J.M., Stoessl, A.J. Neuroscience (2003) [Pubmed]
  3. Cyclosporin-associated akinetic mutism and extrapyramidal syndrome after liver transplantation. Bird, G.L., Meadows, J., Goka, J., Polson, R., Williams, R. J. Neurol. Neurosurg. Psychiatr. (1990) [Pubmed]
  4. Proglumide, a cholecystokinin receptor antagonist, exacerbates beta, beta'-iminodipropionitrile-induced dyskinetic syndrome in rats. Tariq, M., Khan, H.A., Rehana, Z., Al Moutaery, K., Al Deeb, S. Neurotoxicology and teratology. (1998) [Pubmed]
  5. Isolated orofacial dyskinesia: a methylphenidate-induced movement disorder. Senecky, Y., Lobel, D., Diamond, G.W., Weitz, R., Inbar, D. Pediatric neurology. (2002) [Pubmed]
  6. Metoclopramide-induced phantom dyskinesia. Jankovic, J., Glass, J.P. Neurology (1985) [Pubmed]
  7. Oral dyskinesia associated with buspirone use in an elderly woman. Strauss, A. The Journal of clinical psychiatry. (1988) [Pubmed]
  8. PASS assisted search and evaluation of some azetidin-2-ones as C.N.S. active agents. Goel, R.K., Singh, A., Naidu, P.S., Mahajan, M.P., Kulkarni, S.K. Journal of pharmacy & pharmaceutical sciences [electronic resource] : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques. (2005) [Pubmed]
  9. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., Heywood, P. Nat. Med. (2003) [Pubmed]
  10. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients. Ahlskog, J.E., Richelson, E., Nelson, A., Kelly, P.J., Okazaki, H., Tyce, G.M., van Heerden, J.A., Stoddard, S.L., Carmichael, S.W. Ann. Neurol. (1991) [Pubmed]
  11. Clonazepam and phenobarbital in tardive dyskinesia. Bobruff, A., Gardos, G., Tarsy, D., Rapkin, R.M., Cole, J.O., Moore, P. The American journal of psychiatry. (1981) [Pubmed]
  12. The relationship between parkinsonism and tardive dyskinesia. Gerlach, J. The American journal of psychiatry. (1977) [Pubmed]
  13. Paroxysmal tremor and orofacial dyskinesia secondary to a biopterin synthesis defect. Factor, S.A., Coni, R.J., Cowger, M., Rosenblum, E.L. Neurology (1991) [Pubmed]
  14. Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia. See, R.E. Neuropsychopharmacology (1993) [Pubmed]
  15. Piracetam for drug-induced dyskinesia. Chaturvedi, S.K. The Journal of clinical psychiatry. (1987) [Pubmed]
  16. Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turnover as measured by dual probe microdialysis in rats. Grimm, J.W., See, R.E. Neuroscience (2000) [Pubmed]
  17. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. Naidu, P.S., Singh, A., Kulkarni, S.K. Psychopharmacology (Berl.) (2003) [Pubmed]
  18. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Segman, R.H., Heresco-Levy, U., Finkel, B., Inbar, R., Neeman, T., Schlafman, M., Dorevitch, A., Yakir, A., Lerner, A., Goltser, T., Shelevoy, A., Lerer, B. Psychopharmacology (Berl.) (2000) [Pubmed]
  19. Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action. Naidu, P.S., Singh, A., Kulkarni, S.K. Journal of medicinal food. (2003) [Pubmed]
  20. The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. Andreassen, O.A., Finsen, B., Ostergaard, K., Sørensen, J.C., West, M.J., Jørgensen, H.A. Neuroscience (1999) [Pubmed]
  21. Microinjection of sigma ligands into cranial nerve nuclei produces vacuous chewing in rats. Tran, T.T., de Costa, B.R., Matsumoto, R.R. Psychopharmacology (Berl.) (1998) [Pubmed]
  22. Endomorphin-1: induction of motor behavior and lack of receptor desensitization. Mehta, A., Bot, G., Reisine, T., Chesselet, M.F. J. Neurosci. (2001) [Pubmed]
  23. Oral motor disorders in humans. Clark, G.T., Koyano, K., Browne, P.A. Journal of the California Dental Association. (1993) [Pubmed]
  24. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. Ettigi, P., Nair, N.P., Lal, S., Cervantes, P., Guyda, H. J. Neurol. Neurosurg. Psychiatr. (1976) [Pubmed]
  25. Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia. Abílio, V.C., Silva, R.H., Carvalho, R.C., Grassl, C., Calzavara, M.B., Registro, S., D'Almeida, V., Ribeiro, R.d.e. .A., Frussa-Filho, R. Neuropharmacology (2004) [Pubmed]
  26. Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias. Konitsiotis, S., Tsironis, C., Kiortsis, D.N., Evangelou, A. Psychopharmacology (Berl.) (2006) [Pubmed]
  27. Intranigral tachykinin NK3 receptor agonist elicits oral movements in rats. Liminga, U., Johansson, P.E., Gunne, L. Pharmacol. Biochem. Behav. (1991) [Pubmed]
  28. Effects of buspirone on an animal model of tardive dyskinesia. Queiroz, C.M., Frussa-Filho, R. Prog. Neuropsychopharmacol. Biol. Psychiatry (1999) [Pubmed]
WikiGenes - Universities